A team of researchers from North America has unveiled a groundbreaking blood test that can detect more than 50 different types of cancer in their early stages, offering new hope for faster and more effective diagnosis.
The test known as Galleri was developed by American biotechnology company Grail Inc. The clinical trial, which involved about 25,000 adults across the United States and Canada, showed that the test could identify a wide range of cancers from a single blood sample. Experts said the result marked a major advancement in early cancer detection.
The study revealed that more than half of the cancers discovered were detected at an early stage when treatment is more effective and survival chances are higher. Researchers said the test achieved high accuracy and could correctly determine the type and location of cancer in most cases.
“The ability to identify different cancers from just one blood draw represents a major step forward in early diagnosis,” the scientists stated. “Detecting cancer before it spreads greatly improves treatment outcomes and reduces mortality rates.”
The Galleri test works by detecting tiny fragments of tumour DNA that circulate in the bloodstream. These fragments, which carry unique genetic signals, allow doctors to trace the specific origin of cancer within the body. Experts explained that the test analyses changes in DNA patterns linked to tumour growth, helping doctors identify cancers that previously had no screening methods.
Scientists believe that with further validation and regulatory approval, the Galleri blood test could soon become a standard tool in cancer screening worldwide. If adopted, it could help millions of people receive early treatment, saving countless lives and transforming how cancer is detected and managed.
